TG Therapeutics Inc

TGTX

Company Profile

  • Business description

    TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

  • Contact

    3020 Carrington Mill boulevard
    Suite 475
    MorrisvilleNC27560
    USA

    T: +1 212 554-4484

    E: ir@tgtxinc.com

    https://www.tgtherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    319

Stocks News & Analysis

stocks

ASX shares plunge but remain undervalued

Shares drop 17% after guidance is revised but we still see value.
stocks

Ask the analyst: Why have markets shunned APA Group?

Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks

The 10 best US dividend stocks

These undervalued stocks with reliable dividends are worth considering.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,577.8021.60-0.25%
CAC 407,490.2837.860.51%
DAX 4020,317.1012.84-0.06%
Dow JONES (US)42,635.20106.840.25%
FTSE 1008,319.6968.660.83%
HKSE19,240.8938.95-0.20%
NASDAQ19,478.8810.80-0.06%
Nikkei 22539,605.09375.97-0.94%
NZX 50 Index12,943.7499.37-0.76%
S&P 5005,918.259.220.16%
S&P/ASX 2008,329.2019.90-0.24%
SSE Composite Index3,211.3918.77-0.58%

Market Movers